• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail

  • Print
  • Share
  • E-mail
Pediatric Labeling Date:  03/31/2004
Trade Name:  Zemplar
Generic Name or Proper Name (*):  paricalcitol
Indications Studied:  Secondary hyperparathyroidism associated with end stage renal disease
Label Changes Summary:  * Safety and effectiveness were examined in a 12 week randomized, double-blind, placebo-controlled study of 29 pediatric patients aged 5-19 years old with end stage renal disease on hemodialysis; information * Primary efficacy analysis revealed 9 of 15 patients in Zemplar group had 2 consecutive 30 % decreases from baseline intact PTH compared with 3 of 14 patients in placebo group * No patients in either group developed hypercalcemia (defined as at least one calcium value >11.2 mg/dL) during study
Product Labeling:  Labeling  Opens a new window
Sponsor:  Abbott
Pediatric Exclusivity Granted Date:  12/08/2003
Therapeutic Category:  Vitamin D analog